Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2024-03-29 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
年度股东大会通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2023 Annual General Meeting (AGM) of 华兰生物工程股份有限公司, including the date, time, location, voting procedures, agenda items, and proxy voting instructions. It contains no financial statements or financial performance data but focuses on the meeting logistics and agenda. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or notices about the AGM itself. The document length (6122 characters) and content confirm it is not a brief announcement but a full notice for the AGM. Therefore, the correct classification is AGM Information (AGM-R).
2024-03-29 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 11th meeting of the 8th Board of Directors of 华兰生物工程股份有限公司. It includes approvals of various reports such as the 2023 Annual Report, 2023 Annual Financial Report, ESG report, internal control report, and profit distribution plan. It also mentions that these reports are published elsewhere (on 巨潮资讯网 and other media) and will be submitted to the 2023 Annual General Meeting for approval. The document is 4238 characters long, which is relatively short and primarily serves as a formal announcement of board meeting resolutions rather than the full annual report itself. It references the annual report and other documents but does not contain the full financial statements or detailed financial data. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of board resolutions and report approvals, not the full Annual Report (10-K) or other detailed reports themselves.
2024-03-29 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项说明" (special explanation) regarding the "控股股东及其他关联方资金占用情况" (funds occupied by controlling shareholders and other related parties) for the fiscal year ending December 31, 2023. It is issued by a certified public accounting firm and references the audit of the 2023 financial statements of 华兰生物工程股份有限公司. The document includes detailed tables summarizing non-operating fund occupation and related party transactions, and it explicitly states it is a special explanation issued according to regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. It is not a full annual report or audit report but a specific regulatory disclosure related to related-party transactions and fund occupation. This type of document fits best under the category of Audit Report / Information (AR), as it is a standalone audit-related report focusing on a specific regulatory compliance issue and financial data verification, not the full annual report or a general regulatory filing. The document length (15,000 characters) and detailed financial data support it being a substantive report rather than a brief announcement or certification. FY 2023
2024-03-29 Chinese
2023年独立董事年度述职报告(刘万丽)
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2023 Annual Work Report" for a company, detailing the independent director's activities, attendance at board and shareholder meetings, committee participation, communication with auditors, and oversight of company governance and financial reporting during the 2023 fiscal year. It includes detailed descriptions of the director's duties, opinions on profit distribution, auditor reappointment, and stock incentive plans. The document is a comprehensive report on the independent director's annual duties and governance oversight rather than a financial report or announcement. It is not a full annual report (10-K), audit report (AR), or earnings release (ER). It is also not a simple announcement or certification. The content fits best with Board/Management Information (MANG) as it relates to the independent director's role and activities within the company's governance structure for the year 2023.
2024-03-29 Chinese
2023年年度审计报告
Regulatory Filings
2024-03-29 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 华兰生物工程股份有限公司 regarding their 11th meeting of the 8th Supervisory Board. It includes approvals of various reports such as the 2023 Supervisory Board Work Report, the 2023 Annual Report and its summary, the 2023 Financial Final Report, profit distribution plan, internal control self-evaluation report, and other governance matters. The document states these reports have been or will be published elsewhere (e.g., on 巨潮资讯 and 证券时报) and that these items require shareholder approval at the 2023 Annual General Meeting. The document itself is a meeting resolution announcement, not the full annual report or financial statements. The length is only 2620 characters, which is short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal announcement of meeting resolutions and approvals related to the annual report and other governance matters, but does not contain the full reports themselves.
2024-03-29 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.